Evidence map›Paper›PMID 30770921›Full record

ArticleBrain : a journal of neurology2019

Selective loss of cortical endothelial tight junction proteins during Alzheimer's disease progression.

Yu Yamazaki, Mitsuru Shinohara, Motoko Shinohara, Akari Yamazaki, Melissa E Murray, Amanda M Liesinger, Michael G Heckman, Elizabeth R Lesser, Joseph E Parisi, Ronald C Petersen and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Brain : a journal of neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed, 1 pooled it
9.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 1 synthesis or guideline pooled it, 188 citations in OpenAlex.

  1. A Meta-Analysis on Presynaptic Changes in Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2024
    Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Observational
  10. Article
  11. Article
  12. Review
  13. BBB dynamics: the lifespan perspective.Scientific reports · 2026
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Yu YamazakiDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Mitsuru ShinoharaDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Motoko ShinoharaDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Akari YamazakiDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Melissa E MurrayDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Amanda M LiesingerDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Michael G HeckmanDivision of Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, FL, USA.
Elizabeth R LesserDivision of Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, FL, USA.
Joseph E ParisiDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Ronald C PetersenDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Dennis W DicksonDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Takahisa KanekiyoDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Guojun BuDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Mayo Clinic in Florida · USMayo Clinic in Arizona · US

Funding

SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
THE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI BU, GUOJUN · 1999 to 2018
$36.9M
Viral Vectors CoreP01NS074969 · NINDS · WASHINGTON UNIVERSITY · PI SNIDER, BARBARA JOY · 2012 to 2021
$13.0M
Integrative translational discovery of vascular risk factors in aging and dementiaRF1AG051504 · NIA · MAYO CLINIC JACKSONVILLE · PI BU, GUOJUN, ERTEKIN-TANER, NILUFER · 2015 to 2019
$9.8M
Clinicopathologic and Neuroimaging Differences in Alzheimer's Disease VariantsR01AG054449 · NIA · MAYO CLINIC JACKSONVILLE · PI MURRAY, MELISSA ERIN · 2017 to 2021
$3.9M
ApoE Receptor Pathways to Intraneuronal AbetaR01AG027924 · NIA · WASHINGTON UNIVERSITY · PI LI, YONGHE · 2006 to 2021
$3.7M
Impact of ApoE2 on aging-related conditionsRF1AG057181 · NIA · MAYO CLINIC JACKSONVILLE · PI KANEKIYO, TAKAHISA · 2018 to 2018
$3.7M
BRAIN LIPID METABOLISM, DENDRITES AND SYNAPSES IN AGING AND ALZHEIMER'S DISEASER01AG035355 · NIA · MAYO CLINIC JACKSONVILLE · PI BU, GUOJUN · 2010 to 2019
$3.1M
ApoE isoform-specific therapy for Alzheimer diseaseRF1AG046205 · NIA · MAYO CLINIC JACKSONVILLE · PI ZHAO, NA · 2019 to 2019
$3.1M
ApoE pathway in cerebrovascular Aβ clearance in Alzheimer’s diseaseR37AG027924 · NIA · MAYO CLINIC JACKSONVILLE · PI BU, GUOJUN · 2017 to 2020
$2.4M
Brain Neurotropic Growth Factor Delivery to Prevent and Treat Alzheimer’s DiseaseR01AG051574 · NIA · NORTH DAKOTA STATE UNIVERSITY · PI KANEKIYO, TAKAHISA, SINGH, JAGDISH · 2016 to 2020
$2.0M
ApoE isoform-specific therapy for Alzheimer diseaseR01AG046205 · NIA · MAYO CLINIC JACKSONVILLE · PI BU, GUOJUN · 2013 to 2017
$1.6M
NIA NIH HHS P50 AG016574NIA NIH HHS R01 AG027924NIA NIH HHS R01 AG035355NIA NIH HHS R01 AG046205NIA NIH HHS R01 AG051574NIA NIH HHS R01 AG054449NIA NIH HHS R37 AG027924NIA NIH HHS RF1 AG046205NIA NIH HHS RF1 AG051504NIA NIH HHS RF1 AG057181NIA NIH HHS U01 AG006786NINDS NIH HHS P01 NS074969
6 · The paper itself

Abstract

While the accumulation and aggregation of amyloid-β and tau are central events in the pathogenesis of Alzheimer's disease, there is increasing evidence that cerebrovascular pathology is also abundant in Alzheimer's disease brains. In brain capillaries, endothelial cells are connected closely with one another through transmembrane tight junction proteins forming the blood-brain barrier. Because the blood-brain barrier tightly regulates the exchange of molecules between brain and blood and maintains brain homeostasis, its impairment is increasingly recognized as a critical factor contributing to Alzheimer's disease pathogenesis. However, the pathological relationship between blood-brain barrier properties and Alzheimer's disease progression in the human brain is not fully understood. In this study, we show that the loss of cortical tight junction proteins is a common event in Alzheimer's disease, and is correlated with synaptic degeneration. By quantifying the amounts of major tight junction proteins, claudin-5 and occludin, in 12 brain regions dissected from post-mortem brains of normal ageing (n = 10), pathological ageing (n = 14) and Alzheimer's disease patients (n = 19), we found that they were selectively decreased in cortical areas in Alzheimer's disease. Cortical tight junction proteins were decreased in association with the Braak neurofibrillary tangle stage. There was also a negative correlation between the amount of tight junction proteins and the amounts of insoluble Alzheimer's disease-related proteins, in particular amyloid-β40, in cortical areas. In addition, the amount of tight junction proteins in these areas correlated positively with those of synaptic markers. Thus, loss of cortical tight junction proteins in Alzheimer's disease is associated with insoluble amyloid-β40 and loss of synaptic markers. Importantly, the positive correlation between claudin-5 and synaptic markers, in particular synaptophysin, was present independent of insoluble amyloid-β40, amyloid-β42 and tau values, suggesting that loss of cortical tight junction proteins and synaptic degeneration is present, at least in part, independent of insoluble Alzheimer's disease-related proteins. Collectively, these results indicate that loss of tight junction proteins occurs predominantly in the neocortex during Alzheimer's disease progression. Further, our findings provide a neuropathological clue as to how endothelial tight junction pathology may contribute to Alzheimer's disease pathogenesis in both synergistic and additive manners to typical amyloid-β and tau pathologies.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseAmyloid beta-PeptidesBlood-Brain BarrierBrainDisease ProgressionEndothelial CellsFemaleHumansMaleMiddle AgedNeocortexNeurofibrillary TanglesPeptide Fragmentstau ProteinsAmyloid beta-PeptidesPeptide Fragmentstau ProteinsTight Junction Proteinsblood–brain barrierclaudin-5neurovascular unitoccludintight junction

Identifiers

PMID30770921
PMCPMC6439325
OpenAlexW2912592608

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.